SLCO1A2

Across TCGA pan-cancer cohorts, SLCO1A2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLCO1A2 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SLCO1A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLCO1A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, STAD, and LUAD are the cancer types where SLCO1A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.233	0.833	<.001	18	view →
STAD	OS	Median	All	0.095	0.539	.006	15	view →
LUAD	DFS	Median	II,III,IV	0.174	0.684	<.001	12	view →
UCEC	DFS	Median	III,IV	0.915	0.528	.028	10	view →
LGG	OS	Median	All	0.388	0.811	.028	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	All	0.668	0.875	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLCO1A2–BRCA (OS)

Open the BRCA breakdown →